TITLE

Encouraging Openness: Is It Just Lip Service?

PUB. DATE
July 2008
SOURCE
Clinical Trials Administrator;Jul2008, Vol. 6 Issue 7, p78
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article examines the effectiveness of efforts to encourage openness and transparency in clinical trials. An internal audit of the Department of Psychiatry at the University of Minnesota in Minneapolis found that 39% of staff did not believe they would be protected from retaliation for blowing the whistle on an alleged violation. It cites the protection received by employers as whistleblowers demonstrated in a case wherein the spinal unit of Medtronic agreed to settle a whistleblower lawsuit accusing it of defrauding Medicare.
ACCESSION #
32682823

 

Related Articles

  • Disclosure of Investigators' Recruitment Performance in Multicenter Clinical Trials: A Further Step for Research Transparency. Dal-RĂ©, Rafael; Moher, David; Gluud, Christian; Treweek, Shaun; Demotes-Mainard, Jacques; CarnĂ©, Xavier // PLoS Medicine;Dec2011, Vol. 8 Issue 12, p1 

    The authors discuss the benefits of increased transparency on recruitment performance in clinical research studies and clinical trials (CTs) to improve credibility in study results and enhance the ethics and management of CTs. They mention the importance of considering the number of participants...

  • Steps to take when starting a CT monitoring service.  // Clinical Trials Administrator;Jul2007, Vol. 5 Issue 7, p75 

    The article offers pieces of advice from people involved in the clinical trial monitoring service at the University of Minnesota in Minneapolis on how to get started with such monitoring service. This program should have no cost on the part of the sponsor investigators and the standards in the...

  • Her is transparantie wat de klok slaat. Beckers, J.; van de Bunt, H. G.; van Wingerde, K. // Justitiele Verkenningen;nov2013, Vol. 39 Issue 7, p35 

    As a result of the democratization of technology we now seem to live in an era of 'Wild-regulation'. Increasingly transparency is considered to be the universal solution to all sorts of problems. In line with this dominant viewpoint there has been a proliferation of whistleblower initiatives in...

  • The Benefit of Transparent Trials. Krall, Ronald // Applied Clinical Trials;Oct2005, Vol. 14 Issue 10, p82 

    Advocates the full disclosure of clinical trial information. Transparency needed to ensure confidence in the reporting of industry-sponsored trials; Development of GSK Clinical Trial Register by GlaxoSmithKline PLC which provides information about all the sponsored trials of the company;...

  • GSK to Shine Light on Raw Clinical Trial Data. Powers, Marie // BioWorld International;10/17/2012, Vol. 17 Issue 42, p1 

    The article reports on the decision of GlaxoSmithKline plc (GSK) to take extraordinary measures toward data transparency. The company revealed plans to speed up its open innovation approach to research and development (R&D). Access has been given by the company to researchers to detailed...

  • GlaxoSmithKline expands clinical trial disclosures. Arnold, Matthew // Medical Marketing & Media;May2009, Vol. 44 Issue 5, p12 

    The article reports on the decision of GlaxoSmithKline (GSK) to expand its transparency policies to include the disclosure of its clinical research and the company's physicians who works on clinical trials. The company is said to expand the publication of its Clinical Study Register research to...

  • Shortages and Sunshine. Wechsler, Jill // Pharmaceutical Executive;Apr2012, Vol. 32 Issue 4, p14 

    The article focuses on the efforts to increase transparency in the pharmaceutical industry through requiring more disclosure including results of clinical research studies, payments to doctors, and manufacturing issues such as shortage of vital supplies. The U.S. Congress intends to make...

  • The Competitive Logic of Global Clinical Trials. Petryna, Adriana // Social Research;Fall2011, Vol. 78 Issue 3, p949 

    The article discusses clinical trials for new drugs, examining the global clinical trials industry, pharmaceutical companies which conduct trials in middle- and low-income countries, and political aspects in the creation of centralized registries for trials. The author looks at the development...

  • SEC, CFTC Offer Insights on Whistleblower Programs. Mont, Joe // Compliance Week;Jul2012, Vol. 9 Issue 102, p38 

    Information on a panel discussion at the Compliance Week 2012 in Washington, D.C. from June 4-6 is presented. Securities and Exchange Commission (SEC) Deputy Chief Jane Norberg notes that the agency has received an average of seven tips on market manipulation and corporate disclosure in a day....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics